Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

More countries than ever have antimicrobial resistance (AMR) plans, but having a plan doesn't mean patients are protected. New WHO data shows only 22% of countries have fully funded and implemented their national AMR action plans, leaving major gaps in diagnostics, treatment guidelines, and surveillance. In 2023, roughly 1 in 6 bacterial infections worldwide were antibiotic-resistant.
The world is making progress on paper when it comes to antimicrobial resistance (AMR) — but the real-world picture is far less encouraging. New WHO data released ahead of World AMR Awareness Week (Nov. 18–24) shows that 173 countries now have national AMR action plans, more than double the 79 that did in 2017. The catch? Only 22% of countries have both the funding and full implementation to back those plans up.
The gaps are especially stark in diagnostics. Just 36% of countries have a national reference laboratory capable of testing for bacterial and fungal resistance — well short of the global target of 80% by 2030. Meanwhile, only 63% of countries have guidelines on appropriate antimicrobial use, and just over half have surveillance systems to track antibiotic use and resistance trends. To help bridge the divide, WHO released two new practical tools under its AMR Diagnostic Initiative to support clinical labs in diagnosing resistant infections.
By the Numbers:
Why it matters: AMR threatens the effectiveness of antibiotics that underpin routine medical care — from surgeries to childbirth to cancer treatment. Without better diagnostics and implementation, even the best-written national plans won't keep drug-resistant infections from spreading.